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Progressive nodular histiocytosis (PNH) is an uncommon disorder. It belongs to the 
non -  Langerhans cell histiocytic group. The main pathogenic constitutive element 
is the dermal dendrocyte. These processes are considered by some to represent a 
spectrum of a single disease1"3,5.
A patient with progressive nodular histiocytosis is described with peculiarities that 
have not been reported in the English literature thus far5,6,14"18.
Histiocytic disorders are currently identified by their component cells. The non- 
Langerhans Cell Histiocytoses (non-LCH) are a group of disorders defined by the 
accumulation of histiocytes that do not meet the phenotypic criteria for the diagnosis 
of LCH. They consist of a long list of diverse disorders which have been difficult to 
categorize5,6. A conceptual way to simplify these disorders is based on 
immunophenotyping and clinical presentation6,7'12.
The histiocytoses are reactive or malignant conditions in which various tissues, 
including the skin, are infiltrated by cells of the monocyte macrophage lineage5.
They are a heterogeneous group of disorders that are unique by their rarity and by 
the large number of terms that have been used to describe them6.
In 1985 The Writing Group of the Histiocyte Society1 reclassified the histiocytoses 
into three classes:
Class 1: Langerhans cell histiocytosis.
Class 3: Malignant histiocytoses.
This pragmatic classification has been universally adopted. It still leaves, however, 
an enormous group of Class 2 histiocytoses that are very diverse.
These conditions have only been anecdotally reported in the literature, but few with 
completeness with respect to histology and immune- histochemistry6,8'10.
Histiocytes are a diverse group of cells, having the CD34 bone marrow precursor as 
their progenitor cell2 entering a number of ontological pathways to finally become 
morphologically recognizable cells in the skin and other tissues1,2. One type of 
histiocyte was first identified in 1986 by Hedington3, who termed the cell 'a dermal 
dendrocyte'. Unfortunately, little is known about the kinetics and turnover of the 
dermal dendrocyte and, although we assume that the bone marrow CD34 cell is the 
precursor, this has not been scientifically demonstrated1. Dermal dendrocytes are 
MHC Class II antigen positive, suggesting a role in antigen presentation, but 
functional studies on their immune function have not been conducted to date3,5,6.
An important surface marker for the dermal dendrocyte is the blood clotting 
transglutaminase Factor Xllla. The presence of this factor on the dermal 
dendrocytes has led to speculation that this cell could have a function in controlling 
blood loss following damage to the superficial plexus of blood vessels in the skin.
In human skin, dermal dendrocytes are found in the upper papillary dermis 
perivascularly and around adnexal structures.
Studies have shown that a number of these entities share the same 
immunophenotype. These include benign cephalic histiocytosis, juvenile 
xanthogranuloma, generalized eruptive histiocytosis, xanthoma disseminatum and 
progressive nodular histiocytosis4
In all of these conditions, Factor XIII cells are found. In one large study, biopsies 
from benign cephalic histiocytosis, generalized eruptive histiocytosis and juvenile 
xanthogranuloma were examined. In all specimens examined, three distinct patterns 
of proliferation of histiocytes were observed; papillary dermal, lichenoid and 
diffuse4'5-12’15.
In benign cephalic histiocytosis, generalized eruptive histiocytosis and early non- 
xanthomatous juvenile xanthogranuloma, the three conditions could not be 
specifically differentiated from each other on histopathological grounds2’3,5. With 
time, the juvenile xanthogranulomas become more xanthomatized and can then be 
more specifically differentiated from the other two entities.
Histiocytic disorders are currently identified by their component cells. In the right 
clinical context, lesional cells that are CD1a()/Langerin|D/S100|D can be identified as 
Langerhans cell histiocytosis (LCH) cells without looking for ultrastructural Birbeck 
granules1,2. The non-Langerhans cell histiocytoses (non-LCH) are a diverse group 
of disorders defined by the accumulation of histiocytes that do not meet the 
phenotypic criteria for the diagnosis of Langerhans cells (LCs). Although some may
have a haemophagocytic component, the definition excludes primary and secondary 
forms of haemophagocytic lymphohistiocytosis (HLH)3.
In general, the type of histiocyte that makes up the majority of a given lesion can be 
matched to a counterpart in the normal developmental cycle of the histiocyte. Much 
of this knowledge arises from studies done in vitro. In fact, from recent studies, the 
view is emerging that the cells of the mononuclear phagocytic system, including 
LCs, may evolve from a number of different precursors including monocytes, 
lymphocytes and possibly even mesenchymal cells1-3,15
At present, however, it still appears that most histiocytes arise from the CD34|d stem 
cell which, driven by cytokines in the cellular microenvironment, develops along two 
major pathways, to CD14 negative or positive cells. The CD14 cell in the presence 
of TNFa and GMCSF develops into the LC while the CD14t> cell develops either into 
the interstitial/ dermal dendrocyte or the monocyte/macrophage depending on the 
cytokine-environment1
There is continuing modulation between cells in the various developmental 
pathways, driven by changes in the microenvironment2.
From a clinical point of view, it remains useful to divide histiocytic disorders into 
those arising from dendritic cells such as LCs and dermal dendrocyte and those 
arising from the macrophage line. The dermal dendrocyte has as one of its 
hallmarks positive immunostaining for factor XII la and seems to be the precursor cell 
of many of the non-LCH 3. The dermal dendrocyte can be found in cutaneous and 
extracutaneous sites, which would explain the occurrence of the extracutaneous
forms of the diseases. It has been suggested that these cells should more correctly 
be termed interstitial dendritic cells 4’6'8.
The non-LCH are benign proliferative disorders which clinically can be divided into 
three major groups—
1) those that predominantly affect the skin,
2) those that affect the skin but have a systemic component as a major part of the 
disease, and
3) those such as Erdheim- Chester disease (ECD) and sinus histiocytosis with
massive lymphadenopathy (SHML) (Rosai-Dorfman disease) that primarily involve 
extracutaneous sites, although skin may be part of the disease spectrum14,15.
1.2 The Juvenile Xanthogranuloma (JXG) Family
The non-LCH histiocytoses consist of a long list of diverse disorders, which have 
been difficult to categorize and even more difficult to remember. Based on studies 
done by Zelger et al5 and later Chu6 it is shown that the lesional cell of most of the 
non-LCH have the identical immunophenotype, being Factor Xllla positive, 
particularly at the early stages, as well as CD68, CD163, fascin and CD14 positive, 
S100 and CD1a negative. This suggests that these diseases form a spectrum of the 
same disorder and that they derive from the same precursor ce ll. Zelger et al5, 
Chu6, and others have since referred to these disorders as the JXG family. Only a 
few of the non-LCH appear to derive from a different cell line, the most important 
examples of these non-JXG family disorders are SHML (Rosai Dorfman disease) 
and multicentric reticulohistiocytosis (MRH).
This concept of the JXG family is similar to what is found in LCH, in which wide 
spectrums of clinical forms of disease share the identical immunophenotype.
In their attempt to formulate a unifying concept for the non-LCH, Zelger et al5 
described five major morphologic types of histiocytes namely scalloped, vacuolated, 
xanthomatised, spindle-cell, and oncocytic5. They found that JXG is usually 
polymorphous with all five types of histiocytes recognizable morphologically and that 
the other cutaneous histiocytoses are usually largely monomorphous and could be 
defined by a specific histiocyte, as well as by the clinical features of the disease. 
Chu6 took the concept forward by suggesting that the various cell types form a 
continuum along a pathway of maturation, from the early scalloped cell through 
vacuolated to xanthomatized to the mature spindle shaped cells. Chu6 also 
suggested that the more mature the histiocyte, the more resistant the disease to 
adjuvant therapy. Thus he felt that benign cephalic histiocytosis (BCH), generalized 
eruptive histiocytosis (GEH) and JXG represent the most immature end of the 
spectrum, occurring earlier in life and presenting with disease that usually resolves 
spontaneously.
At the more mature end of the spectrum is xanthoma disseminatum (XD) in which 
the disease resolves but usually only after many years, and at the later stage is 
dominated by spindle-shaped histiocytes19,20( See Fig 1).
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Fig 1. At the extreme end of the spectrum is progressive nodular histiocytosis 
(PNH), a disease of mature spindle-shaped cells, which is very resistant to 
treatment9 .
The disease is progressive and although spontaneous involution may occur after 
many years, patients may be left with severe disfigurement8,10,15"18. Although these 
concepts remain unproven, considerable evidence exists to support them.
Numerous cases have been described that show one type of lesion beside 
another11,12 as have patients with lesions that follow a time cycle with progression 
from immature histiocytes to the more mature cells13'15,18,19. Lesions of BCH have 
been shown pathologically to mature to lesions typical of JXG, and some authors 
now refer to BCH as early JXG8. Similarly GEH has been shown to be a precursor of 
JXG, XD, and of PNH. Finally strong expression of MS-1 protein, a high molecular 
weight protein specific for sinusoidal endothelial cells and dendritic perivacular 
histiocytes, was found in all non- LCH cells tested, but not LCH. The strong 
cytoplasmic MS-1 expression in small lesional histiocytes, with expression confined
to a rim surrounding the xanthomatized center of large xanthomatoid and 
multi nucleated cells, also suggests a common maturation pathway for these cells 
and for these disorders5. A similar picture has been seen in LCH with recurrences, 
sometimes years later at the site of an earlier proven LCH lesion, but with a 
phenotype that suggests that the constitutive cells are more mature than the 
previous LCH cells, with loss of CD1a/ Langerin, upregulation of surface HLA-DR, 
and increased fascin expression3.
If we accept the concept that disorders that are clinically present quite differently 
may be due to the same basic cell type at different stages of maturation, then the 
long list of non-LCH disorders may be made more understandable and certainly 
easier to remember and to teach, by considering them in the context of early, middle 
and late maturation stage6,7.
Whether histiocyte morphology can be used for pathologic diagnosis however as 
suggested by Zelger3 is controversial, and some pathologists believe that the 
morphology is too variable to be used in this fashion, as might be expected if the 
diseases are occurring from cells at varying stages along a continuum (See Fig 2).
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Fig 2. This illustration depicts the maturation and progressive spindling of 
histiocytic cells in these disorders. It further highlights the progression of the 
disease, in particular our case on PNH (Progressive nodular Histiocytosis)9
1.3 Diagnosis Of The Non-LCH 
1.3.1 Histopathology
Histopathology is used to diagnose the presence of a non-LCH, but differentiation 
between the different subtypes is based mostly on immunohistochemistry and the
clinical setting.
The basic histopathology of the non-LCH shows well circumscribed nodules with a 
dense infiltrates of histiocytes. Those that involve skin usually mainly infiltrate the 
dermis. Multinucleate giant cells in variable numbers are present, and there is a 
variable degree of predominantly perivascular and perilesional inflammatory cells. 
Touton4 giant cells (seen in 85% of cases of JXG, in a recent series), but not limited 
to JXG, are characterized by a wreath of nuclei around a homogenous eosinophilic 
cytoplasmic center, while the periphery shows prominent xanthomatization15.
Electron microscopy has revealed a variety of non-specific organelles including 
dense bodies, worm-like bodies and popcorn bodies amongst others16. In MRH and 
solitary reticulohistiocytoma multinucleate giant cells and histiocytes containing an 
eosiniphilic “ground glass” material are characteristically found8"10,23.
Thus lesional cells, taken in context, that are positive for factor XII la, CD68, CD163, 
fascin, CD68, and CD14 and that are negative for CD1a, S100, Langerin and/or 
Birbeck granules are diagnostic of the JXG family. MRH, on the other hand is 
defined by histiocytes and multinucleated giant cells that are factor XII la negative, 
CD68 positive and appear to derive from the macrophage line, as do the constitutive 
S100|d cells of SHML (Rosai-Dorfman disease)26.
The final group of conditions that lack markers for LCH, JXG, or macrophage 
lineage, but are clearly dendritic in nature have been referred to as dendritic cell 
histiocytosis when CD1a negative, and as indeterminate cell histiocytosis when they 
are CD1a positive but lack Birbeck granules on EM. Cases usually occur de novo 
but lesions occurring at the same site as previous LCH but which appear to have lost 
the CD1a positivity, have been seen17.
The therapy for all solitary lesions is primarily surgical excision and subdivision 
appears to serve no useful function.
1.3.2 Clinical Diagnosis
Once the diagnosis of “JXG family” is made on immunohistochemistry, the various 
diseases can be defined by the clinical setting, that is, whether they are solitary, 
multiple, or disseminated, the areas of the body involved and the age of the 
patient8,1012,15,16,18.
Thus, JXG is divided into cutaneous and extracutaneous forms. Multiple cutaneous 
lesions confined to the head and neck area in a young child is BCH, multiple skin 
lesions occurring in adolescence or young adults with prominent involvement of 
flexures as well as viscera and mucosa, and comprising mainly xanthomatized cells 
is XD, multiple lesions appearing in crops, generally sparing the flexures and 
occurring in normolipemic patients is GEH, while multiple lesions arising in skin of an 
older patient and progressing to form large nodules, with no evidence of 
spontaneous regression and comprising mainly spindle-shaped histiocytes5,6, is 
PNH.
The reason for the variations in presentation of what appears to be the same 
disorder, may be due to differing immune responses to what may essentially be the 
same initiating factor/s. Cytokines can activate macrophages and modulate their 
phenotype, and the clinicopathologic variations seen are likely to be due to differing 
“cytokine microenvironments”5. A variation in host response could explain the 
predilection of specific diseases according to the age and gender of the patient. 
Thus, the majority of BCH and JXG occur in young children, XD characteristically
affects males in their late teens or early twenties, PNH affects elderly patients of 
either gender5, and MRH usually begins in the fourth decade and predominantly 
affects women23. All of these disorders have been rarely described in children 
however.
All of the disorders considered here are uncommon and pose significant diagnostic 
challenges. From a clinical point of view, however, they share some important 
characteristics6-8.
In general, non-LCH in very young children are usually widespread but tend to be 
benign and self-limited6.
With increasing age5, JXG is more likely to be present as a solitary lesion but most 
still involute spontaneously.
In adults, non-LCH including adult XG, most commonly occur as solitary lesions 
which tend however, not to undergo spontaneous involution. The majority are cured 
by excision. Generalized lesions in adults are less common, but when they occur 
they rarely regress spontaneously, and chemotherapy and radiation therapy often 
have little impact on the course of the disease5,6 (See Table 1). Finally, all of these 
disorders may be associated with underlying infectious, autoimmune or malignant 
diseases, the likelihood of which increases with increasing age and is most 
commonly seen in MRH23
Table 1. Classification of the non langerhans cell histiocytoses group of 
conditions. Highlighted is PNH (progressive nodular histiocytosis), in which 
our patient fitted the typical features as discussed.6,8
Histiocytoses
Diagnosis Age range No. of lesions Appearance Sites of predeliction Natural history
JXG 0 18 (median 2 years) Sing}e:muluple 9:1 Reddish progressing Head and neck can be Gradual involution
to yellow brown any site
<6 months, >M Multiple
disseminated
Same Same Involution
Giant JXG Young >F Single >2 cm Upper extremity/ upper back
Involution
Systemic Median age 0.3 years Single to mnluple Almost 50% have Subcutis, hver, spleen, May involute
JXG (4% of JXG) no skin lesions lung, CNS, ocular fins) N.B. CNS, ocular JXG 
fatalities 4% 10%
Adult XG 18 80 (median 35 years) Single Same as JXG Upper body (not legs) No involution
BCH Young child Few to multiple Reddish tan papules Head and neck Involution or progression to XG
GEH Young adult Multiple Reddish tan papules Face, trunk, arms Involution ordisseminated appears in a  ops spares flexures progression to XG, 
XD, PNH
PNH 40 60 years M St F Multiple 1. Xanthomatous skin Any Progression todisseminated 2. Deeper subcut 
nodules
disfigurement
XD------------------ Late teen young adult Disseminated Yellow/reddish brown Any skin, eyelids Slow involution over
usually <25 years, >M grow forming plaques flexures, mucosae years or progression
and nodules viscera inc. CNS 
transient DI
rare fatalities
MRH 40-+ >F 85% white Multiple Fink reddish brown Dorsum hands, 'coral Progression may
or yellow bead’ peri ungual involute after years
ECD
SHML
7 84 (mean 53 years) Mainly systemic
Mean 206 years 
wide range
Mainly systemic
vermicular around 
nostrils face, pinna, 
arms, legs 
Symmetric erosive 
polyarthritis usually 
precedes rash
Xanthelasma xanthoma Symmetrical long bone 
sclerosis proptosis, 
lung, kidney 
retroperitoneal fibrosis, 
CNS including DI
Firm indurated papules Cervical adenopathy 
80% "B’’symptoms 
48% extranodal skin, 
soft tissue, upper resp 
bone, eye, CNS
/dural K w A r tV r
Disabling arthrius in 
some patients
High fatality rate 
lung fibrosis resp/ 
cardiac failure
Exacerbations and 
remissions often 
self limited (years) 
5% 11% fatalities
JXG -  Juvenile Xanthogranuloma; BCH -  Benign cephalic histiocytosis; GEH -  generalized eruptive histiocytosis; 
PNH -  progressive nodular Histiocytosis; XD -  Xanthoma Disseminatum; MRH -  Multicentric reticulohistiocytosis; 
ECD -  Erdheim Chester disease; SHML - Sinus histiocytosis with massive lymphadenopathy
Histological examination of benign cephalic histiocytosis, juvenile xanthogranuloma, 
generalized eruptive histiocytosis, xanthoma disseminatum and progressive nodular
histiocytosis shows a spectrum of cell types from plump dendritic histiocytes to 
mature spindle shaped cell. In benign cephalic histiocytosis and juvenile 
xanthogranuloma, the cells appear to be the most immature and the disease has the 
shortest lifespan, resolving after a few months. At the other end of the spectrum, 
progressive nodular histiocytosis is a disease of mature spindle-shaped cells, and 
the disease is progressive with no tendency to spontaneous remission and is very 
resistant to treatment5,6. At the more mature end of the spectrum is xanthoma 
disseminatum where the disease resolves, but usually only after many years and at 
the later stages, is dominated histologically by spindle shaped cells.
With maturation of the dermal dendrocytes in these conditions, the cells appear to 
become less responsive to treatment with radiotherapy or chemotherapy. 
Widespread juvenile xanthogranuloma is sensitive to radiotherapy and 
chemotherapy, while progressive nodular histiocytosis is resistant to all forms of 
therapy. It is possible that early in the disease progressive nodular histiocytosis and 
xanthoma disseminatum may be sensitive to treatment but as the cells become 
more mature, they become resistant to treatment.
The patient fitted the typical pattern of PNH (See Table 2) .There is therefore a 
powerful argument for early aggressive treatment in these conditions, particularly in 
Xanthoma Disseminatum where ocular, central nervous system and meningeal 
involvement can cause significant morbidity, and in progressive nodular histiocytosis 
where the disease causes severe disfigurement6.
Table 2. The differential diagnoses of Progressive nodular histiocytosis5,6.
PNH G EH x o JXG " BCH
Age Adults > children Adults > children Young adults First 2 years Young children
Sex No sex 
predilection
Males > females Males > females Males > females No sex predilection
Skin Multiple Multiple Multiple Single or multiple Few to multiple
lesions, n
Type of Yellowish-brown Crops of reddish-tan Yellowish-brown Reddish-yellow Reddish-brown
lesions papules; deep 
dermal nodules
papules papules that tend 
to coalesce
papules and nodules papules and nodules
Distribution Generalized with 
prominent facial 
involvement
Generalized and 
symmetrical
Generalized with 
prominent flexural 
involvement
Generalized with 
predilection for the 
face and upper trunk
Head and neck
Mucous Yes No Yes Rarely Yes
membranes
Systemic
involvement
Usually not Usually not Diabetes insipidus 
Respiratory tract 
involvement
Rarely Yes
Course Progressive but 
with benign 
behavior
Benign with 
spontaneous 
resolution
Progressive with 
rare fatalities
Spontaneous regression Spontaneous resolution or 
progression to JXG
1.4 Summary of cases previously describes in the literature:
1) The first case of PNH was described in 1978 by authors who described 
themselves as 'lumpers' rather than 'splitters' but could not categorize their 
patient into an existing class of histiocytosis 28 They reported a 9-year-old girl 
who eventually developed hundreds of lesions that were similar clinically and 
histologically to JXG, but were non-regressing and not flexural.
2) An 85-year-old woman from England presented with an intensely pruritic eruption 
of 5 years duration that affected mainly the shoulders and proximal limbs. It was 
particularly pronounced at times of psychological stress, and had failed to 
respond to intermittent mild topical steroids. Examination revealed multiple firm 
flesh-coloured nodules, 1-2 cm in diameter and elevation, clinically in keeping
with nodular prurigo. Smaller monomorphic dermal nodules were also evident, 
particularly on the thighs and upper arms. The face, scalp and flexures were not 
involved, and there was no lymphadenopathy.29
3) A 24 yr old female from Germany who suffered from progressive nodular 
histiocytosis, had two distinct lesions namely superficial xanthomatoid papules up 
to 5 mm and deep nodules and tumours from 1-3 cm. Histologically the nodules 
represented spindle cell xanthogranulomas. The patient had no response to 
treatment and lesions continued a disfiguring course.30
4) A 13-year-old girl from the UK presented with multiple cutaneous histiocytic 
lesions, precocious puberty, growth hormone deficiency and a hypothalamic 
tumour. It was concluded that she had progressive nodular histiocytosis. In this 
patient with cutaneous histiocytosis and a hypothalamic tumour, the coincidental 
onset of cutaneous and endocrine disorders suggests a common cause. 
Furthermore, the hypothalamus is a site of predilection for histiocytic lesions and 
magnetic resonance imaging enhancement excluded the more common 
diagnosis of hamartoma, again supporting the hypothesis that the brain lesion is 
histiocytic. Involvement of the central nervous system has been reported only 
three times previously. In view of the onset in later childhood and progressive 
course, PNH is a more likely diagnosis than JXG.31
5) A 7-year-old Japanese boy presented with a 6-year history of yellow 
maculopapular facial lesions. There was a history of onset at the age of one year, 
when yellow macules and papules had appeared on the cheeks one day after 
falling into a dirty gutter. There was associated thickening of the cheek skin with
gradual enlargement of macular lesions bilaterally. After medical consultation and 
a skin biopsy, he was diagnosed with benign cephalic histiocytosis and was kept 
under regular observation. However, the yellow macules progressed to involve 
his entire cheek on both sides. At the age of 7 years, there were no signs of 
spontaneous resolution. On examination, there were facial plaques with bilateral 
involvement of the lower eyelids, cheeks and chin. Moreover, numerous red- 
brown nodules with a diameter of 0.5-2 cm were associated with these plaques 
and were asymptomatic. When the clinical appearance of the condition was 
compared with the appearance at 4 years of age, it was found that the yellow 
plaques had not resolved and the redbrown nodules had enlarged and were 
increased in number.
This case was considered to be a type of non- Langerhans cell histiocytosis 
(class 2) because of the histological features of the foam cells, Touton giant cells 
and spindle cells and the immunohistochemical results that CD68 and MAC387 
were present but CD1a and S-100 proteins were absent132.
6) A 52-year-old woman from the middle east, who 12 years prior to presentation, 
had begun to develop papules and nodules that appeared gradually and 
displayed a progressive course without any signs of spontaneous resolution. The 
lesions were disfiguring but not painful or pruritic. She had involvement of the 
eyelids but no ectropion. She had decreased vision and optic atrophy, which may 
not have been related to the skin lesions. The lesions were excised with good 
results.33
7) A 34 yr old female from Florida, USA, with a 7-year-history of progressive 
increase in growth and number of skin lesions beginning on the back, and later 
involving the head and neck, was referred for evaluation of obstructive breathing 
and dysphagia. She had multiple pedunculated soft tissue lesions on her 
forehead, eyes, nose, lips, cheeks and back. This case is unique in its clinical 
presentation because of the extent of pharyngeal and laryngeal involvement.34
1.5Objectives and Aims
The aims of this study and thesis is to highlight the rarity of the condition Progressive 
Nodular Histiocytosis. Its is so rare that it has been termed an ‘orphan’ disease, 
thereby little or no funding goes towards research and newer treatment modalities in 
this condition.
The diagnosis of the condition relies heavily on experienced pathologists who 
actively look for the features of the disease. It is the hope, that with academic 
awareness, more of these patients will be diagnosed earlier, and thereby greatly 
improving treatment outcomes.
If dermatologists and physicians are made aware of the condition, further 
investigations such as biopsies, etc will be done and pathologists will be asked to 
look for the disease features and ask for special stains. With this, there may be 
many patients who are either misdiagnosed or without diagnosis. This will improve 
treatment outcomes.
Progressive nodular histiocytosis was first described as progressive nodular 
histiocytoma by Taunton et al4. It is a proliferative disorder, mainly of dermal 
dendrocytes, currently classified within the histiocytoses of varied biological 
behaviour and, within these, included in a subgroup of dendritic cell disorders related 
to juvenile xanthogranuloma. This subgroup, which also includes xanthoma 
disseminatum, benign cephalic histiocytosis, progressive nodular histiocytosis, 
spindle cell xanthogranuloma, and generalized eruptive histiocytosis, forms a group 
that is difficult to define because of their clinical overlapping, so that in fact there is a 
tendency towards their unification according to clinical and histopathological
criteria2,3’5> 7.
In 1995 Zelger et al8 reported their histopathological observations regarding this 
type of histiocytosis, describing the pathological features of progressive nodular 
histiocytosis as xanthogranulomas with a predominance of storiform spindle-shaped 
histiocytes, positive to macrophage/dendritic cell line markers (CD68, HAM 56 and 
factor Xllla), as well as SM-actin and HHF35, with no Birbeck granules visible on 
electron microscopic examination. Very few universally accepted reports of 
progressive nodular histiocytosis exist, and these have received diverse 
nomenclature.
The disease is characterized by the progressive appearance of cutaneous and 
mucosal histiocytomas without spontaneous resolution in a normolipaemic state.
Flexural folds and joints are not predominantly involved. Two clinically distinct 
lesions have been reported: superficial, firm, round or pedunculate, yellowish-brown 
tumours and deep purplish nodules with overlying telangiectasia. They often grow to 
a large size (0.4-5 cm). Histologically, the lesions consist of a fibrohistiocytic 
infiltrate with multinucleated and foamy cells. Characteristically specific stains for 
lipids (oil red O stain) and iron (Gomori’s stain) are positive.
Therefore, the appearance after childhood, progressive nature without spontaneous 
resolution, no predilection for the flexural folds , and the absence of systemic 
involvement, are characteristic of progressive nodular histiocytoma5'8,18 (See table 
3).
Progressive nodular histiocytosis is characterized by an intense involvement of the 
face where the lesions tend to group resulting in the typical morphology of leonine 
facies. Hereditary progressive mucinous histiocytosis9 is an inherited disease. 
Typically the lesions are smaller and histological studies demonstrate the presence 
of mucin.
Table 3._Diagnostic criteria for progressive nodular histiocytosis
1 Presence of two distinct types of skin lesion, with multiple occurrence 
and generalized distribution8
2 Progressive course®
3 Histopathology consistent with xanthogranuloma
4 Immunohistochemistry consistent with non-Langerhans cell 
histiocytoses (CD68-positive, CD1a-negative, S-100 protein-negative)
5 Absence of Birbeck granules on electron microscopy
‘a’ -  Diagnostic criteria that must be present to make the diagnosis of PNH
The non-LC histiocytic disorders may be clinically divided into those mainly affecting 
the skin (the cutaneous histiocytoses), those with skin plus a major systemic 
component, and those that are mainly systemic. Despite their clinical diversity, the 
majority appear to originate from a common precursor and form part of a spectrum 
of a single disorder.
It is pragmatic to subdivide these disorders (according to immunohistochemical 
criteria) into JXG family members and non-JXG. It is possible that early on, 
progressive nodular histiocytosis may be sensitive to treatment. There is therefore a 
powerful argument for early aggressive treatment as the disease causes severe 
disfigurement, before dermal dendrocytes have differentiated into xanthomatized or 
spindle-shaped variants5"7.
Our patient presented with an extremely rare variant of Histiocytosis, and to date, is 
the first reported case in Africa. It is also the first case reported in a black male.
2. SUBJECTS AND METHODS
This was an extremely rare case and there was therefore only one subject of the 
case report. This patient was seen from 2008 up to 2012 and was fully 
investigated at the Charlotte Maxeke Hospital. All investigations and tests are 
fully paid for.
Special investigations included the following :
- Chest X-Rays, High resoloution CT Chest, PET scan
- Immunohistochemistry performed on histopathological specimens
- Numerous Blood investigations
Consent for photographs and research was obtained from the patient and ethics 
clearance was given (see Appendix 1).
Methods of processing of histology specimens as follows:
Specimens of skin removed for pathological examination ideally should contain a 
representative sample of epidermis, dermis and subcutaneous tissue. The 
sample should be transported in fixative (usually 10% neutral buffered formalin)
In the laboratory
Fixation
The purpose of fixation is to preserve the skin specimen indefinitely in a life-like 
state. For normal histological sections, the specimen of skin is immediately 
placed in formol saline (formalin). It remains in this preservative for a minimum of 
24 hours prior to processing by a histotechnologist.
Formalin fixes the tissue by forming cross-links between lysine residues in the 
proteins, which does not alter their structure. It is buffered with phosphate to 
prevent acidity provoked by tissue hypoxia, maintaining a pH of 7. It penetrates 
effectively into the tissue but rather slowly, depending on its thickness; tissues 
can be fixed faster if they are warmed.
If no fixative is available at the time of biopsy, the specimen should be kept moist 
with saline and transported to the laboratory as soon as possible, contacting the 
lab in advance to confirm that there will be someone available to receive it.
Tissue processing
The technologist assigns the specimen a unique accession number, examines it 
and describes the gross appearance of the specimen. If malignancy is 
suspected, the edges of the specimen may be marked with ink to identify 
excision margins. All or parts of the specimen are placed into one or more small 
plastic cassettes which hold and identify the tissue while it is being processed, 
and which acts as the backing for the final paraffin block. Initially, the cassettes 
are placed into a fixative.
Paraffin blocks are then prepared to allow the tissue to be cut into thin 
microscopic sections (3-5 microns). Using an automated processor, the water is 
removed from the tissue by alcohol dehydration. The alcohol is cleared using 
xylene and then the tissue is ready to be embedded in paraffin wax. The 
technician removes the tissue from its cassette, aligns it carefully in a mould and
pours hot paraffin wax over it. As the wax cools, it solidifies to form the block 
ready for sectioning.
Sectioning
The embedded tissue is cut into sections using a microtome, which moves the 
block across a very sharp knife every 3 to 5 microns. The sections are then 
floated on a warm water bath, picked up on a glass microscope slide and dried in 
a warm oven.
Preparation of the specimen
Skin fragments in cassette Completed paraffin block Sectioning the biopsy
Microtome Water bath to collect section Staining machine
Staining
By another automated process, the paraffin is removed from the sections by 
sequentially immersing in xylene, then alcohol and then water. The slide is then 
stained routinely using haematoxylin & eosin (H & E). This is an automated
process in larger laboratories, but some centres stain manually. In some 
situations, other special stains may be used.
Haematoxylin stains include a variety of metal cations that result in varying hues 
(blue). It is a basic dye that stains the nucleic acids of the cell nucleus and is 
usually partially removed by an acid-alcohol solution.
Eosin stains are acidic and dye cytoplasmic components of the cell red.
Mounting
The stained slide is processed again through water, alcohol and xylene. A resin 
is applied to glue a cover slip or plastic film in place over the section. The slide is 
now ready for the pathologist to examine and report the microscopic description, 
the diagnosis and comments.
3. CASE REPORT
3.1. History
A 50-year-old black male from Johannesburg, South Africa, presented with skin 
lesions that began 25 yrs ago. There was no family history of note. He was a 
resident of SA, and had no history of travel into Central Africa.
There was progressive evolution of cutaneous lesions, which had increased in size 
and number, with associated mechanical deformities.
Physical examination showed multiple disseminated cutaneous lesions, consisting of 
papules and nodules in a generalized distribution, with sparing of the axillae or 
inguinal areas. Some of them were small, corresponding to lesions of just a few 
months' evolution, and others large, of longer duration (See Fig 7 and Fig 8). They 
involved the head (face, scalp and auricular regions), neck, trunk and extremities.
Fig. 4 Trunk
Their colour was heterogeneous, reddish with greyish tones, and generally smooth 
and shiny on the limbs (See Fig 9 and Fig 10).They were delineated by healthy skin 
and were mostly mounted on the skin, although a few were pediculated. Similar 
nodular lesions were present on the foot.
Fig. 5 Limbs
Fig. 6 Close up -  leg
There were no signs of necrosis or spontaneous regression of the lesions, which on 
palpation were of hard consistency and not painful. The conjunctival, nasal, and 
oropharyngeal mucosae were free of lesions. There were no other physical findings 
of note.
They included the following:
Urea, creatinine, glucose, liver enzymes, total, direct, and indirect bilirubin, alkaline 
phosphatase, electrolytes, creatinine phosphokinase, total proteins, serum 
osmolarity and erythrocyte sedimentation rate, but the results were all normal (N). 
The uric acid concentration was normal. Blood lipid studies showed triglycerides: 
0.97 mmol (N ), total cholesterol: 2.54 mmol (N ), high-density cholesterol lipoprotein 
(HDLc): 0.89 mmol (low), low-density cholesterol lipoprotein (LDLc): 1.99 mmol(N), 
Protein electrophoresis was normal, as were the levels of immunoglobulins, 
rheumatoid factor, ASOT, as well as C3 and C4 complement.
Organ-specific autoantibodies and antinuclear antibodies were negative. Serological 
tests for syphilis, and hepatitis were negative. Urine analysis showed no protein.
3.3. Radiological investigations
Chest X-rays were normal. The bones showed typical degenerative changes for his 
age, with no evidence of osteolytic lesions.
Abdominal ultrasound was done and showed no abnormalities
PET scan showed reactive uptake in the axillary and inguinal lymph nodes (see Fig 
3)
High Resolution CT Chest showed no evidence of pulmonary or cardiac 
involvement. (See Fig 4).
Fig 7. PET scan
Fig 8. High Res CT Chest
Several biopsies were taken. H & E study of the recent lesion showed no epidermal 
alterations, with the dermis presenting a mixed proliferation of xanthomatized and 
scalloped histiocytes with numerous scattered lymphocytes. The older nodule also 
showed a normal epidermis with a dense cellular dermal proliferation with predominant 
spindle-shaped histiocytes, arranged in a storiform pattern. The connective tissue was 
slightly increased. (See Fig 9)
Immunohistochemical study showed strong staining for markers of CD68. S-100 stain 
was negative (See Fig 10 and 11).
No Birbeck granules were seen on electron microscopic examination.Other special 
stains which are specifically positive are HAM-56 and Factor Xllla (See Fig 12).This 
patient was given a trial of radiotherapy without improvement. The distinction from other 
non-LCH, in particular multiple juvenile xanthogranulomas, which may be more likely to 
show spontaneous remission, is somewhat unclear; patients with PNH usually follow a 
serious and disfiguring clinical course.
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4. CONCLUSION
Although PNH is characterized by a progressive course and does not tend towards 
spontaneous resolution, patients usually remain in good general health without visceral 
involvement. The spontaneous regression of some lesions has been an exceptional 
finding in one patient, and systemic disorders in association with PNH have been 
reported in three patients.
The associated findings include chronic myeloid leukemia, hepatosplenomegaly, 
hypothyroidism, hyperuricemia, and hypocholesterolemia in one patient, precocious 
puberty, growth hormone deficiency, and a hypothalamic tumor in a second patient, and 
thrombocytopenia with absent radii (TAR) syndrome in a third. However, no definite 
relationships between these disorders and PNH have yet been established.
The diagnosis of the condition relies heavily on experienced pathologists who actively 
look for the features of the disease. It is the hope, that with academic awareness, more 
of these patients will be diagnosed earlier, and thereby greatly improving treatment 
outcomes.
If dermatologists and physicians are made aware of the condition, further investigations 
such as biopsies, etc will be done and pathologists will be asked to look for the disease 
features and ask for special stains. With this, there may be many patients who are 
either misdiagnosed or without diagnosis. This will improve treatment outcomes.
This is an extremely rare variant of the Histiocytosis group of conditions, and our patient 
is the first reported case in Africa. Our patient did not exhibit any systemic symptoms, 
but regular follow up is mandatory. It is with hope, that additional study of the
immunologic and other host factors responsible for these proliferations may someday 
allow more targeted therapy of these currently resistant forms.
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